ESGPHARM

What this means for you

This application is over — abandoned 17 Oct 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number

90833462

Mark type

Stylized text

Filed

16 Jul 2021

Abandoned

17 Oct 2022

Attorney of record

Diane J. Mason

Goods and services

• Class 040 — Treatment of materials: Custom manufacture of pharmaceuticals; custom manufacturing services in the nature of processing of pharmaceutical preparations; custom manufacturing services in the nature of processing of medicinal materials; custom manufacture of biopharmaceuticals; treatment of biopharmaceutical materials; processing of biopharmaceutical materials for others; custom manufacturing services in the nature of processing of biopharmaceutical materials for others; preservation of pharmaceuticals; custom manufacturing services in the nature of processing of medical products; processing of plant material; processing of plant extracts in the nature of separation of extractants; processing of plants to obtain oils from plant material; processing of biomass; prototype fabrication of new products for others; custom manufacturing services in the nature of processing of plant growth promoting preparations; conversion of targeted substrates into targeted chemical preparations by treatment with enzyme systems; custom manufacture of pharmaceuticals using biological organisms in the manufacturing process; custom manufacturing services in the nature of processing of pharmaceutical preparations using biological organisms; custom manufacture of machines and tools for compressing and compacting powders and granules
• Class 042 — Scientific and technological services: Pharmaceutical research and development; pharmaceutical drug development services; inspection of pharmaceuticals; consultancy in the fields of pharmaceutical research and development; analysis and evaluation of medical product development; research relating to medicines; pharmaceutical drug development services; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; research and development in the field of plant-based biopharmaceutical production; development of pharmaceutical preparations and medicines; medical research in the field of crude drugs; microbial culture trials; protein analysis for scientific research purposes; industrial analysis and research services in the field of protein analysis; genetic engineering services relating to plants; scientific research relating to genetics of plants; providing laboratory research services in the field of gene expression, namely, cancer biology; laboratory services relating to the production of monoclonal antibodies; genetic engineering services relating to plants for pharmaceuticals; scientific research relating to plant breeding for pharmaceuticals
• Class 044 — Medical, beauty and agricultural services: Consultancy and information services relating to pharmaceutical products; advisory services relating to pharmaceutical products; medical consultancy relating to pharmaceutical and medical products; advisory services relating to pharmaceuticals; providing consultancy and information services relating to biopharmaceutical products; pharmaceutical advice; consultancy and information services provided via the Internet relating to pharmaceutical products; cultivation of plants for use in pharmaceuticals for others; farming services in the field of plants used for pharmaceuticals; cultivation of host plants for plant-based biopharmaceutical production for others; plant seed services, namely, providing data, information and analysis in the field of seed performance for medical purposes; information services relating to flora used in pharmaceuticals and medical treatments; plant nursery services; cultivation of plants for use in the development of biopharmaceuticals for others; provision of gene therapy for medical treatment purposes; provision of genetic information for medical treatment purposes; analysis of human biodata for medical purposes; DNA analysis for medical purposes; genetic testing for medical purposes

Owner

• G+FLAS Life Sciences, Seoul, KR

Prosecution history

• 21 Mar 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
• 21 Mar 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
• 21 Mar 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
• 20 Mar 2023 — ASSIGNED TO EXAMINER
• 14 Apr 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 14 Apr 2022 — NON-FINAL ACTION E-MAILED
• 14 Apr 2022 — NON-FINAL ACTION WRITTEN
• 06 Apr 2022 — ASSIGNED TO EXAMINER
• 20 Sept 2021 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 20 Jul 2021 — NEW APPLICATION ENTERED